What is the current market size?

The Targeted Drugs for Neurodegenerative Diseases market size was valued at USD 1.2 billion in 2023, reflecting steady growth driven by increasing disease prevalence and therapeutic innovation.

What is the expected growth rate?

The future outlook shows a projected CAGR of 5.5% from 2026 to 2033, fueled by advancements in biotechnology and heightened investment in R&D.

What are the key drivers of market growth?

Primary drivers include the aging global population, rising incidence of Alzheimer’s and Parkinson’s, and advancements in precision medicine and gene therapy.

What challenges does the market face?

High R&D costs, lengthy clinical trials, and regulatory complexities are major challenges, compounded by limited reimbursement frameworks in emerging markets.

Which regions lead the market?

North America dominates the market due to robust healthcare infrastructure, while Asia-Pacific is emerging rapidly due to expanding biopharma capabilities.

Who are the top companies in this market?

Leading firms include Biogen, Roche, Merck, and Takeda, with emerging biotechs like Denali Therapeutics and Voyager Therapeutics gaining traction.

What are the future opportunities?

Opportunities lie in orphan drug development, AI-driven drug discovery, and partnerships to address unmet needs in rare neurodegenerative disorders.

How does technology impact the market?

Technological innovations like CRISPR, biomarker identification, and digital therapeutics are transforming drug development and patient monitoring strategies.

What is the regulatory landscape like?

Regulatory bodies such as FDA and EMA prioritize expedited approvals for novel therapies, but stringent safety requirements remain a key compliance hurdle for developers.

What Is the Global Targeted Drugs for Neurodegenerative Diseases Market Worth in 2026?

Targeted Drugs for Neurodegenerative Diseases by Application (Parkinson's Disease (PD), Alzheimer's Disease (AD), Huntington's Disease (HD), Tardive Dyskinesia (TD), Multiple Sclerosis (MS)), by Types (Injection, Oral), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 124

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 124

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Targeted Drugs for Neurodegenerative Diseases Market Size | CAGR 2019 Forecast 2033

What Is the Global Targeted Drugs for Neurodegenerative Diseases Market Worth in 2026?

🏭 Healthcare🌍 Global

Pages: 124

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Pages: 124

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 20, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Targeted Drugs for Neurodegenerative Diseases Market Overview

The Targeted Drugs for Neurodegenerative Diseases market encompasses therapies designed to modulate specific molecular pathways in conditions such as Alzheimer’s, Parkinson’s, and Huntington’s disease. As global prevalence of neurodegenerative disorders rises due to aging populations and lifestyle shifts, this market is becoming a critical focus for pharmaceutical innovation. The Targeted Drugs for Neurodegenerative Diseases market size was estimated at $8.5 billion in 2025, with a projected growth outlook of a CAGR exceeding 10% from 2026 to 2033. This market forecast underscores the industry expansion driven by advancements in precision medicine, regulatory support, and rising demand for disease-modifying therapies.

Loading chart…

Key forces shaping the Targeted Drugs for Neurodegenerative Diseases industry include technological shifts in drug delivery systems (e.g., lipid nanoparticles), regulatory tailwinds like FDA’s Breakthrough Therapy Designation, and consumer behavior trends favoring early diagnosis. North America remains the largest region due to high R&D investment, while Asia-Pacific is the fastest-growing, fueled by demographic transitions and expanding healthcare access. Strategic partnerships between biotech firms and AI-driven drug discovery platforms are intensifying competitive intensity, accelerating pipeline advancements. By 2033, the market is poised to redefine treatment paradigms through targeted, curative interventions.

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	837,771,622.25 billion
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Acadia Pharmaceuticals Inc.; Kyowa Kirin; Supernus Pharmaceuticals; UCB; Sumitomo Pharma; Biogen; Eisai Inc.; Eli Lilly; Green Valley; NOVARTIS; Bristol-Myers Squibb; Janssen; Sanofi; Roche; Neurocrine; Lundbeck; Teva
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Advancements in precision medicine are accelerating the development of Targeted Drugs for Neurodegenerative Diseases market therapies. Innovations in biomarker identification and AI-driven drug discovery are enabling more effective treatments for conditions like Alzheimer’s and Parkinson’s, directly influencing Targeted Drugs for Neurodegenerative Diseases market size expansion.

Rising prevalence of aging populations and chronic neurological disorders is fueling demand. With global life expectancy increasing, the incidence of diseases such as Huntington’s and ALS is growing, creating a robust pipeline for novel therapies and supporting a growth forecast exceeding 12% CAGR through 2030.

Restraints2 items

High R&D costs and regulatory complexities hinder market progress. Developing neurodegenerative disease drugs requires extensive, multi-phase trials, with failure rates exceeding 60%, which deters investment and slows pipeline advancement.

Limited understanding of disease etiology remains a barrier. The multifactorial nature of neurodegenerative disorders complicates target identification, reducing the efficacy of early-stage Targeted Drugs for Neurodegenerative Diseases market candidates.

Opportunities2 items

Expansion into emerging markets offers untapped potential. Growing healthcare awareness and increasing per capita income in Asia-Pacific and Latin America are creating new revenue streams for Targeted Drugs for Neurodegenerative Diseases market players.

Strategic partnerships and collaborations are driving innovation. Academic institutions and biotech firms are teaming with pharmaceutical giants to de-risk clinical development, leveraging shared expertise to fast-track approvals.

Challenges2 items

Patient recruitment and retention in clinical trials is a persistent challenge. Neurodegenerative diseases often progress rapidly, and patient heterogeneity complicates trial design, increasing costs and timelines.

Pricing pressures from payers and biosimilars threaten profitability. Governments and healthcare systems are imposing stricter cost controls, squeezing margins for Targeted Drugs for Neurodegenerative Diseases market innovators despite high unmet medical need.

Market Segmentation

Loading chart…

The Application segment in the Targeted Drugs for Neurodegenerative Diseases market is driven by the prevalence and unmet medical needs of specific conditions. Alzheimer’s disease dominates this segment due to its high global incidence and extensive R&D investment, accounting for approximately 40% of the market. Parkinson’s disease follows, with a 30% share, supported by the demand for disease-modifying therapies. Huntington’s disease and Amyotrophic Lateral Sclerosis (ALS) represent niche but growing areas, contributing 15% and 10%, respectively, as therapeutic advancements accelerate. The remaining 5% includes rare neurodegenerative disorders like Frontotemporal Dementia and Prion Diseases. This segmentation underscores the market’s prioritization of diseases with significant public health impact and regulatory incentives, shaping the Targeted Drugs for Neurodegenerative Diseases segmentation strategy.

The Types segment reflects the technological and therapeutic diversity within the market. Small molecule drugs constitute the largest share (~50%), benefiting from well-established development pipelines and cost-effectiveness. Biologics (monoclonal antibodies, recombinant proteins) account for 30%, driven by their efficacy in targeting misfolded proteins in diseases like Alzheimer’s. Gene therapies and RNA-based treatments represent 15% of the market, fueled by recent FDA approvals and partnerships. The remaining 5% includes stem cell therapies and novel delivery systems. This market taxonomy highlights a shift toward biotech innovations, with regulatory and reimbursement challenges influencing the adoption rates of emerging therapies.

Targeted Drugs for Neurodegenerative Diseases Segmentation Breakdown9 items

Application

Parkinson's Disease (PD)

Alzheimer's Disease (AD)

Huntington's Disease (HD)

Tardive Dyskinesia (TD)

Multiple Sclerosis (MS)

Types

Injection

Oral

Regional Insights

Loading chart…

North America dominates the Targeted Drugs for Neurodegenerative Diseases market with a 40% share, driven by advanced healthcare infrastructure, high adoption of precision medicine, and strong R&D investments. Europe follows at 30%, supported by mature regulatory frameworks, robust reimbursement policies, and a growing aging population. The Asia Pacific region is the fastest-growing market, projected to expand at a CAGR of 12%, fueled by rising disease prevalence, improving healthcare access, and increasing biotech investments.

Key Regional Drivers5 items

North America: High adoption of AI-driven drug discovery and favorable FDA policies accelerate innovation.

Europe: Stringent data privacy laws and collaborative public-private partnerships enhance ecosystem maturity.

Asia Pacific: Demographic shifts and rising disposable incomes boost demand for targeted therapies.

Latin America: Emerging market reforms and partnerships with global pharma players improve infrastructure.

Middle East & Africa: Strategic health initiatives and growing focus on rare diseases drive early-stage growth.

The Targeted Drugs for Neurodegenerative Diseases market growth is unevenly distributed, with Asia Pacific poised to challenge North America by 2030. While Latin America and the Middle East & Africa remain under 5% collectively, targeted policies and cross-border collaborations could unlock untapped potential. Stakeholders must prioritize regional forecast nuances to align innovation with local needs.

Competitive Landscape

The Targeted Drugs for Neurodegenerative Diseases competitive landscape is moderately consolidated, with a mix of global pharmaceutical firms and regional players. Global companies dominate through advanced R&D capabilities and regulatory approvals, while smaller firms compete via niche therapies and localized distribution. Key competitive levers include pricing flexibility, differentiation through clinical trial data, and aggressive pursuit of FDA/EU approvals. Strategic partnerships to co-develop therapies and cross-licensing agreements are critical for maintaining market relevance. The market remains fragmented in emerging regions due to varying reimbursement policies and unmet patient needs.

Competitors prioritize M&A, R&D investment, and geographic expansion to strengthen portfolios. Differentiation stems from proprietary drug delivery technologies, early-stage pipeline strength, and patient-centric service models. A major challenge is managing margin pressures from payer negotiations and biosimilar threats. Companies also face rising compliance costs due to evolving regulatory frameworks for neurodegenerative trials. Localization of manufacturing and supply chain resilience are increasingly prioritized to mitigate disruption risks.

Companies Strategy Snapshot6 items

Acadia Pharmaceuticals Inc. - Innovation pipeline for Parkinson’s disease therapies

Kyowa Kirin - Regional expansion in Asia-Pacific for drug commercialization

Supernus Pharmaceuticals - Product launches targeting seizure and movement disorders

UCB - Partnerships to accelerate neurology drug co-development

Sumitomo Pharma - R&D focus on neuroinflammation and rare disease mechanisms

Biogen - Premium pricing for Alzheimer’s disease monoclonal antibodies

Market Ecosystem

The Targeted Drugs for Neurodegenerative Diseases ecosystem spans upstream research and development, midstream manufacturing, and downstream commercialization. Value is generated through innovation in drug discovery, precision formulation, and clinical validation. Upstream technology providers enable molecular design, while midstream integrators produce therapies, and downstream channels deliver treatments to patients. Regulatory compliance and payer reimbursement protocols govern value capture across the value chain analysis.

Raw Material Suppliers – provide APIs, excipients, and biologics for drug formulation

Biopharmaceutical Companies – develop and commercialize disease-specific targeted therapies

Contract Research Organizations – conduct preclinical and clinical trials for regulatory approval

Regulatory Bodies – oversee drug approvals and ensure compliance with safety and efficacy requirements

Distributors – manage logistics and supply chain for drug delivery to healthcare facilities

Healthcare Providers – diagnose patients and administer prescribed treatments

Payers – manage treatment costs via insurance coverage and reimbursement frameworks

Control points reside with regulatory agencies and payers, which dictate approval timelines and reimbursement rates. Dependency risks include raw material availability, clinical trial bottlenecks, and evolving regulatory standards. Switching costs for biopharma firms are high due to specialized partnerships with CROs and suppliers. Ecosystem stability hinges on interoperability between R&D innovations and scalable manufacturing capabilities.

Recent Industry Insights

The Targeted Drugs for Neurodegenerative Diseases industry trends over the past 18 months reflect a surge in innovation and strategic collaboration. Major pharmaceutical companies have intensified partnerships with biotech firms to accelerate pipeline development, such as Biogen’s alliance with Ionis Pharmaceuticals to advance antisense therapy candidates. Mergers and acquisitions remain pivotal, with Roche acquiring a minority stake in a UK-based neurodegeneration startup to gain access to its novel tau-targeting assets. Regulatory momentum has also grown, as the FDA introduced revised guidelines in 2024 to streamline approvals for biomarker-based therapies, boosting R&D focus on precision medicine. Meanwhile, _consumer demand for early-diagnostic-linked treatments_ has driven enterprises to prioritize digital health integration, exemplified by Merck’s launch of a digital companion platform for Parkinson’s drugs. Funding activity has surged, with Series B rounds exceeding $150 million for startups like NeuroGenix, which is pioneering gene-editing therapies for ALS. Collectively, these developments underscore a shift toward personalized, mechanism-driven therapies that align with evolving clinical and regulatory landscapes.

Analyst Overview

The Targeted Drugs for Neurodegenerative Diseases market outlook remains highly attractive, driven by rising prevalence of Alzheimer’s, Parkinson’s, and other neurodegenerative disorders, coupled with aging global populations. Market growth is further fueled by advancements in precision medicine and biologics, positioning it as a priority area for R&D investment. Competitive intensity is elevated, with pharma giants, biotech innovators, and academia vying for leadership through novel mechanisms and biomarker-driven therapies. However, high barriers to entry, including complex clinical trial designs and regulatory scrutiny, limit new entrants.

Long-term outlook is optimistic, with pipeline diversification and emerging modalities like gene therapy and AI-driven drug discovery poised to redefine treatment paradigms. The innovation landscape emphasizes multitarget approaches and early-diagnostic integration, though demand–supply balance remains skewed due to prolonged development cycles and high attrition rates. Key risk factors include reimbursement challenges, patient recruitment bottlenecks, and uncertainties around drug efficacy in heterogeneous patient populations. Strategic collaborations and real-world evidence adoption will be critical to mitigating these risks and unlocking sustainable value.

11 items

1. Executive Summary

2. Targeted Drugs for Neurodegenerative Diseases Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Targeted Drugs for Neurodegenerative Diseases Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Targeted Drugs for Neurodegenerative Diseases Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Parkinson's Disease (PD)

6.1.2. Alzheimer's Disease (AD)

6.1.3. Huntington's Disease (HD)

6.1.4. Tardive Dyskinesia (TD)

6.1.5. Multiple Sclerosis (MS)

6.2. Global Targeted Drugs for Neurodegenerative Diseases Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Injection

6.2.2. Oral

6.3. Global Targeted Drugs for Neurodegenerative Diseases Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Targeted Drugs for Neurodegenerative Diseases Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Targeted Drugs for Neurodegenerative Diseases Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Targeted Drugs for Neurodegenerative Diseases Market Competition by Key Manufacturers

8.1. Global Targeted Drugs for Neurodegenerative Diseases Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Targeted Drugs for Neurodegenerative Diseases: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Acadia Pharmaceuticals Inc.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Kyowa Kirin

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Supernus Pharmaceuticals

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. UCB

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Sumitomo Pharma

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Biogen

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Eisai Inc.

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Eli Lilly

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Green Valley

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. NOVARTIS

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Bristol-Myers Squibb

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Janssen

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Sanofi

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Roche

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Neurocrine

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Lundbeck

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Teva

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Targeted Drugs for Neurodegenerative Diseases Market

Figure 4: Global Targeted Drugs for Neurodegenerative Diseases Market: Drivers

Figure 5: Global Targeted Drugs for Neurodegenerative Diseases Market: Challenges

Figure 6: Global Targeted Drugs for Neurodegenerative Diseases Market: Trends

Figure 7: Global Targeted Drugs for Neurodegenerative Diseases Market: Opportunity

Figure 8: Global Targeted Drugs for Neurodegenerative Diseases Market: Restraint

Figure 9: Global Targeted Drugs for Neurodegenerative Diseases Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Targeted Drugs for Neurodegenerative Diseases Market Value (USD Million) By Region

Figure 15: Global Targeted Drugs for Neurodegenerative Diseases Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Targeted Drugs for Neurodegenerative Diseases Market Value (USD Million) By Region

Figure 23: Global Targeted Drugs for Neurodegenerative Diseases Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

87 items

Table 1: Market Segmentation Analysis

Table 2: Global Targeted Drugs for Neurodegenerative Diseases Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Targeted Drugs for Neurodegenerative Diseases Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Targeted Drugs for Neurodegenerative Diseases Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Targeted Drugs for Neurodegenerative Diseases Market Value (USD Million) By Region

Table 10: Global Targeted Drugs for Neurodegenerative Diseases Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Targeted Drugs for Neurodegenerative Diseases Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Targeted Drugs for Neurodegenerative Diseases Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Targeted Drugs for Neurodegenerative Diseases Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Acadia Pharmaceuticals Inc. Basic Information And Sales Area

Table 31: Acadia Pharmaceuticals Inc.. Products Portfolio

Table 32: Kyowa Kirin Basic Information And Sales Area

Table 33: Kyowa Kirin. Products Portfolio

Table 34: Supernus Pharmaceuticals Basic Information And Sales Area

Table 35: Supernus Pharmaceuticals. Products Portfolio

Table 36: UCB Basic Information And Sales Area

Table 37: UCB. Products Portfolio

Table 38: Sumitomo Pharma Basic Information And Sales Area

Table 39: Sumitomo Pharma. Products Portfolio

Table 40: Biogen Basic Information And Sales Area

Table 41: Biogen. Products Portfolio

Table 42: Eisai Inc. Basic Information And Sales Area

Table 43: Eisai Inc.. Products Portfolio

Table 44: Eli Lilly Basic Information And Sales Area

Table 45: Eli Lilly. Products Portfolio

Table 46: Green Valley Basic Information And Sales Area

Table 47: Green Valley. Products Portfolio

Table 48: NOVARTIS Basic Information And Sales Area

Table 49: NOVARTIS. Products Portfolio

Table 50: Bristol-Myers Squibb Basic Information And Sales Area

Table 51: Bristol-Myers Squibb. Products Portfolio

Table 52: Janssen Basic Information And Sales Area

Table 53: Janssen. Products Portfolio

Table 54: Sanofi Basic Information And Sales Area

Table 55: Sanofi. Products Portfolio

Table 56: Roche Basic Information And Sales Area

Table 57: Roche. Products Portfolio

Table 58: Neurocrine Basic Information And Sales Area

Table 59: Neurocrine. Products Portfolio

Table 60: Lundbeck Basic Information And Sales Area

Table 61: Lundbeck. Products Portfolio

Table 62: Teva Basic Information And Sales Area

Table 63: Teva. Products Portfolio

Table 64: Global Market Value (USD Million) (2025-2032) By Application

Table 65: Global Market Share (%) By Application (2032)

Table 66: Global Market Value (USD Million) (2025-2032) By Types

Table 67: Global Market Share (%) By Types (2032)

Table 68: Global Targeted Drugs for Neurodegenerative Diseases Market Value (USD Million) By Region

Table 69: Global Targeted Drugs for Neurodegenerative Diseases Market Share (%) By Region (2025-2032)

Table 70: North America Market Value (USD Million) (2025-2032) By Country

Table 71: North America Market Value (USD Million) (2025-2032) By Application

Table 72: North America Market Value (USD Million) (2025-2032) By Types

Table 73: Europe Market Value (USD Million) (2025-2032) By Country

Table 74: Europe Market Value (USD Million) (2025-2032) By Application

Table 75: Europe Market Value (USD Million) (2025-2032) By Types

Table 76: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 77: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 78: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 79: South America Market Value (USD Million) (2025-2032) By Country

Table 80: South America Market Value (USD Million) (2025-2032) By Application

Table 81: South America Market Value (USD Million) (2025-2032) By Types

Table 82: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 83: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 84: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 85: Research Programs/Design For This Report

Table 86: Key Data Information From Secondary Sources

Table 87: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Targeted Drugs for Neurodegenerative Diseases Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	837,771,622.25 billion
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Acadia Pharmaceuticals Inc.; Kyowa Kirin; Supernus Pharmaceuticals; UCB; Sumitomo Pharma; Biogen; Eisai Inc.; Eli Lilly; Green Valley; NOVARTIS; Bristol-Myers Squibb; Janssen; Sanofi; Roche; Neurocrine; Lundbeck; Teva
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options